Clinical Trial

Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer

Study acronym: HYPOSIB
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible. Investigators initiated this multicenter two-armed phase III prospective trial to analyse the non-inferiority of hypofractionation with simultaneous integrated boost in patients with early breast cancer in comparison to standard fractionation.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2015-06-17; most recent amendment 2024-03-19.
Status change: Recruiting → Active, Not Recruiting 2021-08-19
Status change: Not Yet Recruiting → Recruiting 2015-07-14
Trial Details
NCT Number NCT02474641
Lead Sponsor University Hospital Schleswig-Holstein
Collaborators: University of Luebeck
Conditions Early-Stage Breast Carcinoma
Enrollment 2,324 participants
Start Date 2015-06-16
Primary Completion 2019-01-08 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-21